Targovax ASA: Fourth quarter 2021 results
Oslo, Norway, 17 February 2022 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its fourth quarter 2021 results. Targovax’s CEO will give an online presentation and update on the clinical program to investors, analysts and the press at 10:00 CET today (details below).2021 HIGHLIGHTS ONCOS-102 · Reported class-leading ORR of 35% for ONCOS-102 in PD1-refractory melanoma, associated with broad and powerful immune activation in responding tumors · Reported 25.0 months median Overall